| Drug Name |
Natalizumab |
| Drug ID |
BADD_D01537 |
| Description |
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. |
| Indications and Usage |
For treatment of multiple sclerosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA23 |
| DrugBank ID |
DB00108
|
| KEGG ID |
D06886
|
| MeSH ID |
D000069442
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
64406-008 |
| UNII |
3JB47N2Q2P
|
| Synonyms |
Natalizumab | Tysabri | Antegren |
